drugset / Trial / NCT04238975

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults

NCT04238975

Phase 2 Unknown 213 enrolled Green Cross Corporation
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to evaluate safety and efficacy (immunogenicity) of a single dose of GC3111 versus Boostrix® vaccine among healthy adults in 19-64 years of age.

Timeline

Start
2019-10-14
Primary completion
2021-02
Completion
2021-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Boostrix Vaccine 0.5 ml Intramuscular
Subject GC3111 Vaccine 0.5 ml Intramuscular